052260 — Hyundai BioLand Co Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesAdventurousSmall CapNeutral

Annual income statement for Hyundai BioLand Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	R2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	88,899	102,802	99,154	96,720	119,519
Cost of Revenue
Gross Profit	17,298	37,291	35,650	39,795	52,846
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	105,823	116,447	91,775	81,741	106,029
Operating Profit	-16,924	-13,645	7,378	14,979	13,490
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-17,921	-15,165	6,844	17,446	15,884
Provision for Income Taxes
Net Income After Taxes	-13,545	-11,686	4,764	13,845	12,311
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-13,545	-11,686	4,764	8,056	5,703
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-13,545	-11,686	4,764	8,056	5,703
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-291	153	194	368	484
Dividends per Share